Modelling the Reverse ElectroDialysis process with seawater and concentrated brines

Technologies for the exploitation of renewable energies have been dramatically increasing in number, complexity and type of source adopted. Among the others, the use of saline gradient power is one of the latest emerging possibilities, related to the use of the osmotic/chemical potential energy of concentrated saline solutions. Nowadays, the fate of this renewable energy source is intrinsically linked to the development of the pressure retarded osmosis and reverse electrodialysis technologies. In the latter, the different concentrations of two saline solutions is used as a driving force for the direct production of electricity within a stack very similar to the conventional electrodialysis ones. In the present work, carried out in the EU-FP7 funded REAPower project, a multi-scale mathematical model for the Salinity Gradient Power Reverse Electrodialysis (SGP-RE) process with seawater and concentrated brines has been developed. The model is based on mass balance and constitutive equations collected from relevant scientific literature for the simulation of the process under extreme conditions of solutions concentration. A multi-scale structure allows the simulation of the single cell pair and the entire SGP-RE stack. The first can be seen as the elementary repeating unit constituted by cationic and anionic membrane and the relevant two channels where dilute and concentrate streams flow. The reverse electro-dialysis stack is constituted by a number of cell pairs, the electrode compartments and the feed streams distribution system. The model has been implemented using gPROMS , a powerful dynamic modelling process simulator. Experimental information, collected from the FUJIFILM laboratories in Tilburg (the Netherlands), has been used to perform the tuning of model formulation and eventually to validate model predictions under different operating conditions. Finally, the model has been used to simulate different possible scenarios and perform a preliminary analysis of the influence of some process operating conditions on the final stack performance

REAPOWER – USE OF DESALINATION BRINE FOR POWER PRODUCTION THROUGH REVERSE ELECTRODIALYSIS

Salinity Gradient Power (SGP) represents a viable renewable energy source associated with the mixing of two solutions of different salinities. Reverse Electrodialysis (SGP-RE or RED) is a promising technology to exploit this energy source and directly generate electricity. However, although the principle of this technology is well known since several years, further R&D efforts are still necessary in order to explore the real potential of the SGP-RE process. With this regard, the aim of the REAPower project (www.reapower.eu) is the development of an innovative system for power production by SGP-RE process, using sea (or brackish) water as diluted solution and brine as concentrate. The use of sea or brackish water (instead of fresh water) as diluate allows reducing the electrical resistance of the diluate compartment, increasing the achievable output power. This work presents the R&D activities carried out so far within the REAPower project, particularly focusing on the relevant progresses in membranes development, stack design and process modelling. An extensive experimental campaign has been performed on a lab-scale unit, allowing to reach a power density among the highest so far presented in the open literature. These results provided useful information for the final goal of the project, i.e. the construction of the first SGP-RE system on a small pilot-scale, in order to demonstrate the feasibility of the future scale-up for this technology

Analysis and simulation of scale-up potentials in reverse electrodialysis

The Reverse Electrodialysis (RED) process has been widely accepted as a viable and promising technology to produce electric energy from salinity difference (salinity gradient power - e.g. using river water/seawater, or seawater and concentrated brines). Recent R&D efforts demonstrated how an appropriate design of the RED unit and a suitable selection of process conditions may crucially enhance the process performance. With this regard, a process simulator was developed and validated with experimental data collected on a lab-scale unit, providing a new modelling tool for process optimisation. In this work, performed within the REAPower project (www.reapower.eu), a process simulator previously proposed by the same authors has been modified in order to predict the behaviour of a cross-flow RED unit. The model was then adopted to investigate the influence of the most important variables (i.e. solution properties and stack geometry) on the overall process performance. In particular, the use of different concentrations and flow rates for the feed streams have been considered, as well as different aspect ratios in asymmetric stacks. Moreover, the influence of the scaling-up a RED unit was investigated, starting from a 22x22 cm2 100 cell pairs lab-stack, and simulating the performance of larger stacks up to a 44x88 cm2 500 cell pairs unit. Finally, different scenarios are proposed for a prototype-scale RED plant, providing useful indications for the technology scale-up towards 1 kW of power production, relevant to the installation of a real prototype plant in Trapani (Italy) being the final objective of the R&D activities of the REAPower project

A hierarchical model for novel schemes of electrodialysis desalination

A new hierarchical model for the electrodialysis (ED) process is presented. The model has been implemented into gPROMs Modelbuilder (PSE), allowing the development of a distributed-parameters simulation tool that combines the effectiveness of a semi-empirical modelling approach to the flexibility of a layered arrangement of modelling scales. Thanks to its structure, the tool makes possible the simulation of many different and complex layouts, requiring only membrane properties as input parameters (e.g. membrane resistance or salt and water permeability). The model has been validated against original experimental data obtained from a lab scale ED test rig. Simulation results concerning a 4-stage treatment of seawater and dynamic batch operations of brackish water desalination are presented, showing how the model can be effectively used for predictive purposes and for providing useful insights on design and optimisation

Reverse Electrodialysis with saline waters and concentrated brines: a laboratory investigation towards technology scale-up

The use of concentrated brines and brackish water as feed solutions in reverse electrodialysis represents a valuable alternative to the use of river/sea water, allowing the enhancement of power output through the increase of driving force and reduction of internal stack resistance. Apart from a number of theoretical works, very few experimental investigations have been performed so far to explore this possibility. In the present work, two RED units of different size were tested using artificial saline solutions. The effects of feed concentration, temperature and flowrate on process performance parameters were analysed, adopting two different sets of membranes. These experiments allowed to identify the most favourable conditions for maximising the power output within the presently investigated range, i.e. 0.1 M NaCl as diluate and 5 M NaCl as concentrate at 40°C. Under these conditions a power density equal to 12 W/m2cell_pair was reached, among the highest so far reported in the literature. Increasing the unit size a slight reduction in power density was observed. These results indicate new directions for a successful scale-up and development of the Reverse Eletrodialysis technology

Microsampling and enantioselective liquid chromatography coupled to mass spectrometry for chiral bioanalysis of novel psychoactive substances

In this paper, the development of efficient enantioselective HPLC methods for the analysis of five benzofuran-substituted phenethylamines, two substituted tryptamines, and three substituted cathinones is described. For the first time, reversed-phase (eluents made up with acidic water-methanol solutions) and polar-ionic (eluent made up with an acetonitrile-methanol solution incorporating both an acidic and a basic additive) conditions fully compatible with mass spectrometry (MS) detectors were applied with a chiral stationary phase (CSP) incorporating the (+)-(18-crown-6)-tetracarboxylic acid chiral selector. Enantioresolution was achieved for nine compounds with α and RS factors up to 1.32 and 5.12, respectively. Circular dichroism (CD) detection, CD spectroscopy in stopped-flow mode and quantum mechanical (QM) calculations were successfully employed to investigate the absolute stereochemistry of mephedrone, methylone and butylone and allowed to establish a (R)<(S) enantiomeric elution order for these compounds on the chosen CSP. Whole blood miniaturized samples collected by means of volumetric absorptive microsampling (VAMS) technology and fortified with the target analytes were extracted following an optimized protocol and effectively analysed by means of an ultra-high performance liquid chromatography-MS system. By this way a proof-of-concept procedure was applied, demonstrating the suitability of the method for quali-quantitative enantioselective assessment of the selected psychoactive substances in advanced biological microsamples. VAMS microsamplers including a polypropylene handle topped with a small tip of a polymeric porous material were used and allowed to volumetrically collect small aliquots of whole blood (10 μL) independently from its density. Highly appreciable volumetric accuracy (bias, in the -8.7-8.1% range) and precision (% CV, in the 2.8-5.9% range) turned out

Effects of the dose of erythropoiesis stimulating agents on cardiovascular events, quality of life, and health-related costs in hemodialysis patients: the clinical evaluation of the dose of erythropoietins (C.E. DOSE) trial protocol

<p>Abstract</p> <p>Background</p> <p>Anemia is a risk factor for death, adverse cardiovascular outcomes and poor quality of life in patients with chronic kidney disease (CKD). Erythropoietin Stimulating Agents (ESA) are commonly used to increase hemoglobin levels in this population. In observational studies, higher hemoglobin levels (around 11-13 g/dL) are associated with improved survival and quality of life compared to hemoglobin levels around 9-10 g/dL. A systematic review of randomized trials found that targeting higher hemoglobin levels with ESA causes an increased risk of adverse vascular outcomes. It is possible, but has never been formally tested in a randomized trial, that ESA dose rather than targeted hemoglobin concentration itself mediates the increased risk of adverse vascular outcomes. The Clinical Evaluation of the DOSe of Erythropoietins (C.E. DOSE) trial will assess the benefits and harms of a high versus a low fixed ESA dose for the management of anemia in patients with end stage kidney disease.</p> <p>Methods/Design</p> <p>This is a randomized, prospective open label blinded end-point (PROBE) trial due to enrol 2204 hemodialysis patients in Italy. Patients will be randomized 1:1 to 4000 IU/week versus 18000 IU/week of intravenous epoietin alfa or beta, or any other ESA in equivalent doses. The dose will be adjusted only if hemoglobin levels fall outside the 9.5-12.5 g/dL range. The primary outcome will be a composite of all-cause mortality, non fatal stroke, non fatal myocardial infarction and hospitalization for cardiovascular causes. Quality of life and costs will also be assessed.</p> <p>Discussion</p> <p>The C.E.DOSE study will help inform the optimal therapeutic strategy for the management of anemia of hemodialysis patients, improving clinical outcomes, quality of life and costs, by ascertaining the potential benefits and harms of different fixed ESA doses.</p> <p>Trial registration</p> <p>Clinicaltrials.gov NCT00827021</p

How the First Year of the COVID-19 Pandemic Impacted Patients’ Hospital Admission and Care in the Vascular Surgery Divisions of the Southern Regions of the Italian Peninsula

Background: To investigate the effects of the COVID-19 lockdowns on the vasculopathic population. Methods: The Divisions of Vascular Surgery of the southern Italian peninsula joined this multicenter retrospective study. Each received a 13-point questionnaire investigating the hospitalization rate of vascular patients in the first 11 months of the COVID-19 pandemic and in the preceding 11 months. Results: 27 out of 29 Centers were enrolled. April-December 2020 (7092 patients) vs. 2019 (9161 patients): post-EVAR surveillance, hospitalization for Rutherford category 3 peripheral arterial disease, and asymptomatic carotid stenosis revascularization significantly decreased (1484 (16.2%) vs. 1014 (14.3%), p = 0.0009; 1401 (15.29%) vs. 959 (13.52%), p = 0.0006; and 1558 (17.01%) vs. 934 (13.17%), p &lt; 0.0001, respectively), while admissions for revascularization or major amputations for chronic limb-threatening ischemia and urgent revascularization for symptomatic carotid stenosis significantly increased (1204 (16.98%) vs. 1245 (13.59%), p &lt; 0.0001; 355 (5.01%) vs. 358 (3.91%), p = 0.0007; and 153 (2.16%) vs. 140 (1.53%), p = 0.0009, respectively). Conclusions: The suspension of elective procedures during the COVID-19 pandemic caused a significant reduction in post-EVAR surveillance, and in the hospitalization of asymptomatic carotid stenosis revascularization and Rutherford 3 peripheral arterial disease. Consequentially, we observed a significant increase in admissions for urgent revascularization for symptomatic carotid stenosis, as well as for revascularization or major amputations for chronic limb-threatening ischemia